P963: EVOLUTION OF TREATMENT PATTERNS AND OVERALL SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING A SECOND LINE OF THERAPY BETWEEN 2012 AND 2020: ANALYSIS OF THE PREAMBLE COHORT

MLA

D. Kuter, et al. “P963: Evolution of Treatment Patterns and Overall Survival in Patients with Relapsed/Refractory Multiple Myeloma Receiving a Second Line of Therapy between 2012 and 2020: Analysis of the Preamble Cohort.” HemaSphere, vol. 6, June 2022, pp. 853–54. EBSCOhost, https://doi.org/10.1097/01.HS9.0000846720.60768.ed.

APA

D. Kuter, H. Goldschmidt, D. Cella, M. T. Petrucci, P. Moreau, B. Durie, A. Juarez-Garcia, L. Trong, J. Gu, G. Hernandez Rivera, S. Dhanasiri, T. Marshall, J. Wang, L. Lacoin, K. Ramasamy, & R. Vij. (2022). P963: Evolution of Treatment Patterns and Overall Survival in Patients with Relapsed/Refractory Multiple Myeloma Receiving a Second Line of Therapy between 2012 and 2020: Analysis of the Preamble Cohort. HemaSphere, 6, 853–854. https://doi.org/10.1097/01.HS9.0000846720.60768.ed

Chicago

D. Kuter, H. Goldschmidt, D. Cella, M. T. Petrucci, P. Moreau, B. Durie, A. Juarez-Garcia, et al. 2022. “P963: Evolution of Treatment Patterns and Overall Survival in Patients with Relapsed/Refractory Multiple Myeloma Receiving a Second Line of Therapy between 2012 and 2020: Analysis of the Preamble Cohort.” HemaSphere 6 (June): 853–54. doi:10.1097/01.HS9.0000846720.60768.ed.